Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers

Angelo Moreno, George A. Pitoc, Nancy J. Ganson, Juliana M. Layzer, Michael S. Hershfield, Alice F Tarantal, Bruce A. Sullenger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Biopharmaceuticals have become increasingly attractive therapeutic agents and are often PEGylated to enhance their pharmacokinetics and reduce their immunogenicity. However, recent human clinical trials have demonstrated that administration of PEGylated compounds can evoke anti-PEG antibodies. Considering the ubiquity of PEG in commercial products and the presence of pre-existing anti-PEG antibodies in patients in large clinical trials evaluating a PEG-modified aptamer, we investigated how anti-PEG antibodies effect the therapeutic activities of PEGylated RNA aptamers. We demonstrate that anti-PEG antibodies can directly bind to and inhibit anticoagulant aptamer function in vitro and in vivo. Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents. The most common approach for pharmacokinetic enhancement of biologically inspired therapies is PEGylation; however, possible limitations of this formulation strategy have arisen. Here, we describe how anti-PEG antibodies can inhibit the therapeutic efficacy of a PEGylated RNA aptamer. These findings further highlight emerging issues between the immune system and PEGylated therapeutics.

Original languageEnglish (US)
Pages (from-to)634-644.e3
JournalCell Chemical Biology
Volume26
Issue number5
DOIs
StatePublished - May 16 2019

Fingerprint

Anticoagulants
Polyethylene glycols
Anti-Idiotypic Antibodies
Antibodies
Nucleotide Aptamers
Pharmacokinetics
Clinical Trials
Therapeutics
Therapeutic Uses
Primates
Immune system
Immune System
Pharmaceutical Preparations

Keywords

  • anti-PEG antibodies
  • aptamer
  • aPTT (activated partial thromboplastin time)
  • ELISA (enzyme-linked immunosorbent assay)
  • hypersensitivity
  • PEG (polyethylene glycol)
  • PEGylation
  • RB006
  • REGULATE-PCI
  • rhesus monkeys

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Moreno, A., Pitoc, G. A., Ganson, N. J., Layzer, J. M., Hershfield, M. S., Tarantal, A. F., & Sullenger, B. A. (2019). Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. Cell Chemical Biology, 26(5), 634-644.e3. https://doi.org/10.1016/j.chembiol.2019.02.001

Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. / Moreno, Angelo; Pitoc, George A.; Ganson, Nancy J.; Layzer, Juliana M.; Hershfield, Michael S.; Tarantal, Alice F; Sullenger, Bruce A.

In: Cell Chemical Biology, Vol. 26, No. 5, 16.05.2019, p. 634-644.e3.

Research output: Contribution to journalArticle

Moreno, A, Pitoc, GA, Ganson, NJ, Layzer, JM, Hershfield, MS, Tarantal, AF & Sullenger, BA 2019, 'Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers', Cell Chemical Biology, vol. 26, no. 5, pp. 634-644.e3. https://doi.org/10.1016/j.chembiol.2019.02.001
Moreno, Angelo ; Pitoc, George A. ; Ganson, Nancy J. ; Layzer, Juliana M. ; Hershfield, Michael S. ; Tarantal, Alice F ; Sullenger, Bruce A. / Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. In: Cell Chemical Biology. 2019 ; Vol. 26, No. 5. pp. 634-644.e3.
@article{65f3d42b7d4d4cf5a2c5abe28ac35de6,
title = "Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers",
abstract = "Biopharmaceuticals have become increasingly attractive therapeutic agents and are often PEGylated to enhance their pharmacokinetics and reduce their immunogenicity. However, recent human clinical trials have demonstrated that administration of PEGylated compounds can evoke anti-PEG antibodies. Considering the ubiquity of PEG in commercial products and the presence of pre-existing anti-PEG antibodies in patients in large clinical trials evaluating a PEG-modified aptamer, we investigated how anti-PEG antibodies effect the therapeutic activities of PEGylated RNA aptamers. We demonstrate that anti-PEG antibodies can directly bind to and inhibit anticoagulant aptamer function in vitro and in vivo. Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents. The most common approach for pharmacokinetic enhancement of biologically inspired therapies is PEGylation; however, possible limitations of this formulation strategy have arisen. Here, we describe how anti-PEG antibodies can inhibit the therapeutic efficacy of a PEGylated RNA aptamer. These findings further highlight emerging issues between the immune system and PEGylated therapeutics.",
keywords = "anti-PEG antibodies, aptamer, aPTT (activated partial thromboplastin time), ELISA (enzyme-linked immunosorbent assay), hypersensitivity, PEG (polyethylene glycol), PEGylation, RB006, REGULATE-PCI, rhesus monkeys",
author = "Angelo Moreno and Pitoc, {George A.} and Ganson, {Nancy J.} and Layzer, {Juliana M.} and Hershfield, {Michael S.} and Tarantal, {Alice F} and Sullenger, {Bruce A.}",
year = "2019",
month = "5",
day = "16",
doi = "10.1016/j.chembiol.2019.02.001",
language = "English (US)",
volume = "26",
pages = "634--644.e3",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers

AU - Moreno, Angelo

AU - Pitoc, George A.

AU - Ganson, Nancy J.

AU - Layzer, Juliana M.

AU - Hershfield, Michael S.

AU - Tarantal, Alice F

AU - Sullenger, Bruce A.

PY - 2019/5/16

Y1 - 2019/5/16

N2 - Biopharmaceuticals have become increasingly attractive therapeutic agents and are often PEGylated to enhance their pharmacokinetics and reduce their immunogenicity. However, recent human clinical trials have demonstrated that administration of PEGylated compounds can evoke anti-PEG antibodies. Considering the ubiquity of PEG in commercial products and the presence of pre-existing anti-PEG antibodies in patients in large clinical trials evaluating a PEG-modified aptamer, we investigated how anti-PEG antibodies effect the therapeutic activities of PEGylated RNA aptamers. We demonstrate that anti-PEG antibodies can directly bind to and inhibit anticoagulant aptamer function in vitro and in vivo. Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents. The most common approach for pharmacokinetic enhancement of biologically inspired therapies is PEGylation; however, possible limitations of this formulation strategy have arisen. Here, we describe how anti-PEG antibodies can inhibit the therapeutic efficacy of a PEGylated RNA aptamer. These findings further highlight emerging issues between the immune system and PEGylated therapeutics.

AB - Biopharmaceuticals have become increasingly attractive therapeutic agents and are often PEGylated to enhance their pharmacokinetics and reduce their immunogenicity. However, recent human clinical trials have demonstrated that administration of PEGylated compounds can evoke anti-PEG antibodies. Considering the ubiquity of PEG in commercial products and the presence of pre-existing anti-PEG antibodies in patients in large clinical trials evaluating a PEG-modified aptamer, we investigated how anti-PEG antibodies effect the therapeutic activities of PEGylated RNA aptamers. We demonstrate that anti-PEG antibodies can directly bind to and inhibit anticoagulant aptamer function in vitro and in vivo. Moreover, in parallel studies we detected the presence of anti-PEG antibodies in nonhuman primates after a single administration of a PEGylated aptamer. Our results suggest that anti-PEG antibodies can limit the activity of PEGylated drugs and potentially compromise the activity of otherwise effective therapeutic agents. The most common approach for pharmacokinetic enhancement of biologically inspired therapies is PEGylation; however, possible limitations of this formulation strategy have arisen. Here, we describe how anti-PEG antibodies can inhibit the therapeutic efficacy of a PEGylated RNA aptamer. These findings further highlight emerging issues between the immune system and PEGylated therapeutics.

KW - anti-PEG antibodies

KW - aptamer

KW - aPTT (activated partial thromboplastin time)

KW - ELISA (enzyme-linked immunosorbent assay)

KW - hypersensitivity

KW - PEG (polyethylene glycol)

KW - PEGylation

KW - RB006

KW - REGULATE-PCI

KW - rhesus monkeys

UR - http://www.scopus.com/inward/record.url?scp=85065254546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065254546&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2019.02.001

DO - 10.1016/j.chembiol.2019.02.001

M3 - Article

C2 - 30827937

AN - SCOPUS:85065254546

VL - 26

SP - 634-644.e3

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 5

ER -